سعر ايرالونير 25مجم 20 قرص 2025

Eraloner 25 mg (eplerenone) film-coated tablets, pack of 20, by Multi-Apex (Egypt).

• Heart failure post-myocardial infarction: to improve survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Hypertension: to lower blood pressure, alone or with other antihypertensive agents.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Heart failure post-MI: adverse reactions more frequent than placebo included hyperkalaemia and increased serum creatinine.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Serum potassium > 5.5 mEq/L at initiation.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Creatinine clearance ≤ 30 mL/min.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Concomitant strong CYP3A inhibitors (e.g. ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hyperkalaemia is the principal risk, increased by impaired renal function, diabetes, proteinuria and concomitant drugs that raise potassium or inhibit CYP3A; minimise the risk with patient selection and monitoring.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A inhibitorsContraindicatedStrong CYP3A inhibitors markedly increase eplerenone exposure; concomitant use is contraindicated.DailyMed (U.S. National Library of Medicine)
• Moderate CYP3A inhibitors (e.g. erythromycin, saquinavir, verapamil, fluconazole)Heart failure post-MI: do not exceed 25 mg once daily. Hypertension: start at 25 mg once daily; maximum 25 mg twice daily.DailyMed (U.S. National Library of Medicine)
• ACE inhibitors, angiotensin II receptor blockers and NSAIDsIncrease the risk of hyperkalaemia and renal impairment; check serum potassium and creatinine within 3–7 days of starting them.DailyMed (U.S. National Library of Medicine)

• Published case reports on eplerenone use in pregnancy are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; no adverse developmental effects were seen in rats and rabbits at exposures about 31–32 times human exposure.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No human data on presence of eplerenone in human milk or effects on the breastfed infant or milk production; eplerenone was present in the milk of lactating rats.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Eplerenone: Blocks aldosterone binding at mineralocorticoid receptors (US Inspra label).